Biofrontera Future Growth
Future criteria checks 5/6
Biofrontera is forecast to grow earnings and revenue by 72.2% and 23% per annum respectively while EPS is expected to grow by 73.9% per annum.
Key information
72.2%
Earnings growth rate
73.9%
EPS growth rate
| Pharmaceuticals earnings growth | 21.5% |
| Revenue growth rate | 23.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 25 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 60 | 1 | N/A | N/A | 1 |
| 12/31/2025 | 47 | -7 | N/A | -8 | 2 |
| 12/31/2024 | 39 | -16 | N/A | -3 | 2 |
| 9/30/2024 | 35 | -13 | -18 | -18 | N/A |
| 6/30/2024 | 35 | -14 | -19 | -19 | N/A |
| 3/31/2024 | 33 | -23 | -25 | -25 | N/A |
| 12/31/2023 | 34 | -20 | -25 | -25 | N/A |
| 9/30/2023 | 34 | -26 | -24 | -24 | N/A |
| 6/30/2023 | 29 | -23 | -28 | -28 | N/A |
| 3/31/2023 | 28 | -14 | -18 | -18 | N/A |
| 12/31/2022 | 29 | -1 | -16 | -16 | N/A |
| 9/30/2022 | 28 | -12 | -29 | -29 | N/A |
| 6/30/2022 | 28 | -26 | -24 | -24 | N/A |
| 3/31/2022 | 29 | -29 | -25 | -25 | N/A |
| 12/31/2021 | 24 | -38 | -27 | -27 | N/A |
| 9/30/2021 | 24 | -23 | -6 | -6 | N/A |
| 6/30/2021 | 22 | -10 | -6 | -6 | N/A |
| 3/31/2021 | 19 | -10 | -9 | -9 | N/A |
| 12/31/2020 | 19 | -11 | -12 | -12 | N/A |
| 12/31/2019 | 26 | -11 | -38 | -38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AI10 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: AI10 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AI10 is expected to become profitable in the next 3 years.
Revenue vs Market: AI10's revenue (23% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: AI10's revenue (23% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AI10's Return on Equity is forecast to be high in 3 years time